DURECT Corporation Invites You to Join its Fourth Quarter 2012 Earnings
CUPERTINO, Calif., Feb. 22, 2013
CUPERTINO, Calif., Feb. 22, 2013 /PRNewswire/ --In conjunction with DURECT
Corporation's (Nasdaq: DRRX) fourth quarter 2012 financial results press
release, you are invited to listen to the conference call that will be
broadcast live over the internet on Thursday, February 28, 2013 at 4:30 pm
Eastern Time (1:30 pm Pacific Time).
A live audio webcast of the presentation will be available by accessing
DURECT's homepage at http://www.durect.com and clicking "Investor Relations."
If you are unable to participate during the live webcast, the call will be
archived on DURECT's website under Audio Archive in the "Investor Relations"
About DURECT Corporation
DURECT is a specialty pharmaceutical company developing innovative drugs for
pain and other chronic diseases, with late-stage development programs
including REMOXY^®, POSIDUR^™, ELADUR^®, and TRANSDUR^®-Sufentanil.DURECT's
proprietaryoral, transdermal and injectable depot delivery technologies may
enable new indications and superior clinical/commercial attributes such as
abuse deterrence, improved convenience, compliance, efficacy and safety for
small molecule and biologic drugs.For more information, please visit
NOTE: POSIDUR^™, SABER^®, ORADUR^®, TRANSDUR^®, and ELADUR^® are trademarks of
DURECT Corporation. Other referenced trademarks belong to their respective
owners. REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates
under development and have not been approved for commercialization by the U.S.
Food and Drug Administration or other health authorities.
SOURCE DURECT Corporation
Contact: Matthew J. Hogan, Chief Financial Officer, +1-408-777-4936
Press spacebar to pause and continue. Press esc to stop.